Back to Search Start Over

Spray dried human and chimpanzee adenoviral-vectored vaccines are thermally stable and immunogenic in vivo.

Authors :
Afkhami S
LeClair DA
Haddadi S
Lai R
Toniolo SP
Ertl HC
Cranston ED
Thompson MR
Xing Z
Source :
Vaccine [Vaccine] 2017 May 19; Vol. 35 (22), pp. 2916-2924. Date of Electronic Publication: 2017 Apr 21.
Publication Year :
2017

Abstract

Cold chain-free vaccine technologies are needed to ensure effective vaccine delivery and coverage, particularly in resource-poor countries. However, the immunogenicity and thermostability of spray dried live viral vector-based vaccines such as recombinant adenoviral-vectored vaccines remain to be investigated. To address this issue, we have spray dried human adenoviral (AdHu5)- and chimpanzee adenoviral (AdCh68)-vectored tuberculosis vaccines in a mannitol and dextran matrix. Spray dried powders containing these two vaccines display the morphologic and chemical properties desired for long-term thermostability and vaccination. Upon reconstitution, they effectively transfected the cells in vitro with relatively small losses in viral infectivity related to the spray drying process. Following in vivo vaccination, AdHu5- and AdCh68-vectored vaccines were as immunogenic as the conventional fresh, cryopreserved liquid vaccine samples. Of importance, even after cold chain-free storage, at ambient temperatures and relatively low humidity for 30 and 90days, the vaccines retained their in vivo immunogenicity, while the liquid vaccine samples stored under the same conditions lost their immune-activating capability almost entirely. Our results support further development of our spray drying technologies for generating thermally stable adenoviral-vectored and other viral-vectored vaccines.<br /> (Copyright © 2017 Elsevier Ltd. All rights reserved.)

Details

Language :
English
ISSN :
1873-2518
Volume :
35
Issue :
22
Database :
MEDLINE
Journal :
Vaccine
Publication Type :
Academic Journal
Accession number :
28438408
Full Text :
https://doi.org/10.1016/j.vaccine.2017.04.026